Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:EVLONASDAQ:SCPSNASDAQ:SMFLNASDAQ:VAXX On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeEVLOEvelo Biosciences$0.00$0.00$0.00▼$0.06$6K0.7710,994 shs11 shsSCPSScopus BioPharma$0.00$0.00$0.00▼$0.01$13K-0.292,103 shsN/ASMFLSmart for Life$0.02$0.00$0.00▼$7.68$124K1.633,240 shs2 shsVAXXVaxxinity$0.02+50.0%$0.01$0.00▼$0.50$1.90M-22.535,040 shs111 shs20 High-Yield Dividend Stocks that Could Ruin Your RetirementAlmost everyone loves strong dividend-paying stocks, but high yields can signal danger. Discover 20 high-yield dividend stocks paying an unsustainably large percentage of their earnings. Enter your email to get this report and avoid a high-yield dividend trap.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceEVLOEvelo Biosciences0.00%0.00%-40.00%-40.00%-99.27%SCPSScopus BioPharma0.00%0.00%0.00%0.00%-85.71%SMFLSmart for Life0.00%+1,066.67%+5,733.33%+84.21%-99.39%VAXXVaxxinity0.00%+7,400.00%+50.00%+14,900.00%-72.22%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationEVLOEvelo BiosciencesN/AN/AN/AN/AN/AN/AN/AN/ASCPSScopus BioPharmaN/AN/AN/AN/AN/AN/AN/AN/ASMFLSmart for LifeN/AN/AN/AN/AN/AN/AN/AN/AVAXXVaxxinityN/AN/AN/AN/AN/AN/AN/AN/ACompare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceEVLOEvelo Biosciences 0.00N/AN/AN/ASCPSScopus BioPharma 0.00N/AN/AN/ASMFLSmart for Life 0.00N/AN/AN/AVAXXVaxxinity 0.00N/AN/AN/ACompare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookEVLOEvelo BiosciencesN/AN/AN/AN/AN/AN/ASCPSScopus BioPharmaN/AN/AN/AN/AN/AN/ASMFLSmart for Life$11.11M0.01N/AN/A($17.10) per share0.00VAXXVaxxinityN/AN/AN/AN/A$0.11 per shareN/ACompare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateEVLOEvelo Biosciences-$114.53MN/A0.00∞N/AN/AN/AN/A5/19/2025 (Estimated)SCPSScopus BioPharma-$11.61MN/A0.00∞N/AN/AN/AN/AN/ASMFLSmart for Life-$22.68MN/A0.00∞N/AN/AN/AN/AN/AVAXXVaxxinity-$56.93M-$0.45N/A∞N/AN/AN/AN/AN/ACompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthEVLOEvelo BiosciencesN/AN/AN/AN/AN/ASCPSScopus BioPharmaN/AN/AN/AN/AN/ASMFLSmart for LifeN/AN/AN/AN/AN/AVAXXVaxxinityN/AN/AN/AN/AN/ACompare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipEVLOEvelo Biosciences0.31%SCPSScopus BioPharmaN/ASMFLSmart for Life28.39%VAXXVaxxinity82.95%Insider OwnershipCompanyInsider OwnershipEVLOEvelo Biosciences1.02%SCPSScopus BioPharma5.10%SMFLSmart for Life31.71%VAXXVaxxinity64.06%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableEVLOEvelo Biosciences12018.98 million18.79 millionNo DataSCPSScopus BioPharma942.08 million39.94 millionNot OptionableSMFLSmart for Life1107.09 million4.84 millionNot OptionableVAXXVaxxinity90126.75 million45.55 millionNot OptionableSMFL, VAXX, SCPS, and EVLO HeadlinesRecent News About These CompaniesBrain healthOctober 24, 2024 | newsweek.comTreatment Trials in Alzheimer's DiseaseSeptember 30, 2024 | msn.comIs Vaxxinity Inc (VAXX) Stock a Good Investment?September 19, 2024 | aaii.comCongress makes $4.5 trading stocks in a day; Here's the biggest winnersJuly 4, 2024 | finbold.comVaxxinity UB-312 Parkinson's Trial Results Published in Nature MedicineJune 20, 2024 | globenewswire.comWhy Is Vaxxinity (VAXX) Stock Up 39% Today?May 3, 2024 | investorplace.comWhy Is Vaxxinity (VAXX) Stock Down 58% Today?April 22, 2024 | investorplace.comVaxxinity Plans to Delist Shares From NasdaqApril 19, 2024 | marketwatch.comVaxxinity Issues Shareholder LetterApril 19, 2024 | globenewswire.comVaxxinity Announces Intention to Voluntarily Delist and Deregister its Class A Common StockApril 19, 2024 | globenewswire.comVaxxinity to Present Clinical Data at the Annual Academy of Neurology 2024 Annual MeetingMarch 28, 2024 | globenewswire.comVAXX Stock Earnings: Vaxxinity Beats EPS for Q4 2023March 27, 2024 | investorplace.comVaxxinity Reports Fourth Quarter and Full-Year 2023 Financial Results and Provides Corporate UpdatesMarch 27, 2024 | globenewswire.comVaxxinity Announces Positive Target Engagement Data from Phase 1 Clinical Trial for Parkinson's Disease at AD/PD™ 2024March 7, 2024 | globenewswire.comVaxxinity’s Heart Health Innovation to Reduce LDL Cholesterol LevelsFebruary 15, 2024 | finance.yahoo.comVaxxinity’s Cholesterol Vaccine Candidate Successfully Lowers LDL-C: Preclinical Data PublishedFebruary 15, 2024 | finance.yahoo.comVaxxinity's Cholesterol Vaccine Candidate Successfully Lowers LDL-C: Preclinical Data PublishedFebruary 15, 2024 | globenewswire.comVaxxinity to Present Clinical and Preclinical Pipeline Data at AD/PD 2024February 13, 2024 | finance.yahoo.comVaxxinity, UF Join Forces Against Neurodegenerative DiseasesJanuary 30, 2024 | finance.yahoo.comVaxxinity Announces Research Collaboration on Active Immunotherapies for Neurodegenerative Diseases with University of FloridaJanuary 30, 2024 | finance.yahoo.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeSMFL, VAXX, SCPS, and EVLO Company DescriptionsEvelo Biosciences NASDAQ:EVLO$0.0003 0.00 (0.00%) As of 05/16/2025Evelo Biosciences, Inc., a clinical-stage biotechnology company, focuses on discovering and developing oral medicines that act on immune cells in the small intestine with systemic effects. It is developing EDP1815, a whole-microbe product candidate, which has completed a Phase 2 trial for the treatment of psoriais; and is in Phase 2 clinical trial for the treatment of atopic dermatitis. The company is also developing EDP1867, a non-live pharmaceutical preparation for single strain of Veillonella parvula, which is in Phase 1b clinical trial; EDP2939, an investigational oral biologic for the potential treatment of inflammatory diseases; and EDP1908, a product candidate for oncology. Evelo Biosciences, Inc. was incorporated in 2014 and is headquartered in Cambridge, Massachusetts.Scopus BioPharma NASDAQ:SCPS$0.0003 0.00 (0.00%) As of 05/16/2025Scopus BioPharma Inc., a clinical-stage biopharmaceutical company, focuses on developing transformational therapeutics targeting serious diseases with unmet medical needs. It offers Duet Platform, which consists of signal transducer and activator of transcription 3 (STAT3), a master immune checkpoint inhibitor and toll-like receptor 9 (TLR9), as well as includes CpG-STAT3ASO (DUET-02), CpG-STAT3siRNA (DUET-01), and CpG-STAT3decoy (DUET-03); and that develops a suite of bifunctional oligonucleotides that activate antigen-presenting cells (APCs) in the tumor microenvironment that alleviates tumor immunosuppression to jump-start T cell-mediated immune responses. The company is also developing DUET-01, as a monotherapy targeting B-cell non-Hodgkin lymphoma; DUET-02 that provides systemic delivery for treatment of solid tumors comprising prostate or kidney cancers; and DUET-03, which targets the actual STAT3 transcription factor protein. Scopus BioPharma Inc. has licensing agreements with the City of Hope, National Institutes of Health Program, and The Hebrew University of Jerusalem. The company was formerly known as Project18 Inc. and changed its name to Scopus BioPharma Inc. in December 2017. Scopus BioPharma Inc. was incorporated in 2017 and is headquartered in New York, New York.Smart for Life NASDAQ:SMFL$0.02 0.00 (0.00%) As of 05/16/2025Smart for Life, Inc. acquires, develops, manufactures, operates, markets, and sells nutraceutical and related products in the United States and internationally. It offers natural health and wellness meal replacement products, including nutrition bars, cookies, soups and shakes, vitamins, and supplements under the Smart for Life brand; dietary supplements; and nutritional products, including whey protein isolate powder, tablet supplements for joint health, nitric oxide, post workout blends, Omega-3 supplements, and pre-workout supplements under the Sports Illustrated Nutrition brand for athletes and active lifestyle consumers. The company also provides various nutritional products, including antioxidant rich supplements, plant-based proteins, alkalizing nutrients, and weight management products. It sells its products through online market platforms. The company was formerly known as Bonne Santé Group, Inc. and changed its name to Smart for Life, Inc. in August 2021. Smart for Life, Inc. was founded in 2002 and is based in Boca Raton, Florida.Vaxxinity NASDAQ:VAXX$0.02 +0.01 (+50.00%) As of 05/16/2025 09:45 AM EasternVaxxinity, Inc., a biotechnology company, focuses on developing product candidates for human use in the fields of neurology, cardiovascular diseases, and coronaviruses in the United States. Its product pipeline comprises UB-311, which is in phase 2 clinical trial that targets toxic forms of aggregated amyloid-b in the brain to fight alzheimer's disease; UB-312, which is in phase 1 clinical trial that targets toxic forms of aggregated a-synuclein in the brain to fight parkinson's disease and other synucleinopathies, such as Lewy body dementia and multiple system atrophy; and VXX-301, which is in preclinical trial, an anti-tau product candidate for various neurodegenerative conditions, including alzheimer's disease, traumatic brain injury, and chronic traumatic encephalopathy. It also develops VXX-401, which is phase 1 clinical trial that targets proprotein convertase subtilisin/kexin type 9 serine protease to lower low-density lipoprotein cholesterol and reduce the risk of cardiac events; UB-313 that targets calcitonin gene-related peptide to fight migraines; and UB-612, neutralizes the SARS-CoV-2 virus and is in phase 3 clinical trial. The company was incorporated in 2021 and is headquartered in Merritt Island, Florida. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas MarketBeat Week in Review – 05/12 - 05/16 Retail Investors Are Betting Big on Rocket Lab—Should You Too? Meta's 5 Key Pillars for AI Growth—Zuckerberg's Bold Vision Taiwan Semiconductor Stock Is The Gift That Keeps on Giving GE Aerospace: Qatar Deal Fuels Multi-Billion Dollar Growth Engine Alibaba's Earnings Just Changed Everything for the Stock Plug Power: Is Q1 Noise An Opportunity for Accumulation? Cisco Stock Eyes New Highs in 2025 on AI, Earnings, Upgrades Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
